Loading
IT
Indaptus Therapeutics, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Anderson Glen R., was filed 16 Aug 2023.
Indaptus Therapeutics, Inc.: what insiders have been doing
Indaptus Therapeutics, Inc. belongs to the Healthcare & Pharma sector. Filings by its managers are published through SEC (Form 4). 5 insiders have disclosed 5 filings since 22 October 2025.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of Indaptus Therapeutics, Inc. stock was filed. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 7 days. For comparison, the SEC allows two business days to file a Form 4.
Across the 5,462 companies tracked on its exchange, the median is 28 filings; at 5 filings, this issuer sits below that mark. The full history, which starts in 2021, counts 16 purchases against 2 sales. For the fiscal year to 31 December 2025, the annual 10-K puts net income at -20.8 m USD.
Other companies in the same sector with recent insider buying flagged by our signals: Xenon Pharmaceuticals Inc. and Vivos Inc. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
26
Thresholds
n/a
Buy Volume
€449,329
16 ops. · all time
Sell Volume
€89,232
2 ops. · all time
Since the insiders bought
- -31.0%Entry US$66.92 · Close at T+365 US$46.20
- +11.5%Entry US$46.20 · Close at T+365 US$51.52
- +16.4%Entry US$50.51 · Close at T+365 US$58.80
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.63
Analyst consensus
Income statement
EBITDA-US$19.8M
Net income-US$20.8M0.0% margin
Valuation
P/Book30.9x
Beta0.97
Balance sheet & cash
Market capUS$350.4M
Free Cash Flow-US$14.8M
Profitability & ownership
ROE-318.0%
ROA-98.1%
% insiders82.4%
% institutions0.3%
Last declaration on 22 January 2026
Declarations26 total
25,000 shares0Common StockSEC:0001493152-26-003293:0
216,617 shares@ US$2.0345.9% of flowCommon StockSEC:0001493152-25-029355:0
26,758 shares@ US$2.03100.0% of flowCommon StockSEC:0001493152-25-029356:0
52,204 shares@ US$2.0377.5% of flowCommon StockSEC:0001493152-25-029354:0
54,421 shares@ US$2.0399.6% of flowCommon StockSEC:0001493152-25-029353:0
6,068 shares@ US$8.30245.2% of flowCommon StockSEC:0001641172-25-021376:0
42,553 shares@ US$1.1755.8% of flowCommon stockSEC:0001493152-24-047808:0
84,932 shares@ US$1.82517.4% of flowCommon stockSEC:0001493152-24-030839:0
44,354 shares@ US$1.94100.0% of flowCommon StockSEC:0001493152-23-029212:0
Canonical exit: 8 Nov 2023 (T+90)
35,064 shares@ US$2.12Common StockSEC:0001493152-23-029212:1
Canonical exit: 9 Nov 2023 (T+90)
23,934 shares@ US$2.34Common StockSEC:0001493152-23-029212:2
Canonical exit: 12 Nov 2023 (T+90)
50 shares@ US$4.09Common StockSEC:0001493152-22-035926:1
Canonical exit: 31 May 2022 (T+90)
500 shares@ US$1.83Common StockSEC:0001493152-22-035926:2
Canonical exit: 20 Feb 2023 (T+90)
500 shares@ US$1.87Common StockSEC:0001493152-22-035926:3
Canonical exit: 1 Mar 2023 (T+90)
100 shares@ US$4.65100.0% of flowCommon StockSEC:0001493152-22-035926:0
Canonical exit: 1 May 2022 (T+90)
9,600 shares@ US$1.90Common stockSEC:0001493152-22-033241:1
Canonical exit: 19 Feb 2023 (T+90)
400 shares@ US$1.76370.1% of flowCommon stockSEC:0001493152-22-033241:0
Canonical exit: 16 Feb 2023 (T+90)
10,308 shares@ US$2.803.5% of flowCommon stockSEC:0001493152-22-025578:0
Canonical exit: 7 Dec 2022 (T+90)
150 shares@ US$2.620.4% of flowCommon stockSEC:0001493152-22-025450:0
Canonical exit: 6 Dec 2022 (T+90)
8,632 shares@ US$2.57Common stockSEC:0001493152-22-025319:1
Canonical exit: 6 Dec 2022 (T+90)
1,060 shares@ US$2.440.3% of flowCommon stockSEC:0001493152-22-025319:0
Canonical exit: 5 Dec 2022 (T+90)
19,727 shares@ US$2.635.9% of flowCommon stockSEC:0001493152-22-016027:0
Canonical exit: 4 Sept 2022 (T+90)
14,130 shares@ US$5.00Common StockSEC:0001493152-22-003002:1
5,870 shares@ US$5.000122.5% of flowCommon StockSEC:0001493152-22-003002:0
11,187 shares@ US$5.827.0% of flowCommon StockSEC:0001493152-21-029297:0
Canonical exit: 16 Feb 2022 (T+90)
25 of 26 declarations
About Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. (ticker: INDP) is a U.S.-listed biotechnology company trading on Nasdaq, therefore on the NYSE/NASDAQ ecosystem, with headquarters in New York, United States. The company is a clinical-stage biotech focused on developing novel therapies for cancer and viral infections. Its corporate history is relatively recent and reflects a 2021 restructuring and rebranding around the Decoy Biosystems asset, after which the business began operating as Indaptus Therapeutics. As is typical for an early-stage biotech, the company remains heavily R&D-driven, has limited operating history, and depends on external capital to advance development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1857044/000149315221018935/form8-k.htm?utm_source=openai))
Indaptus’ core business is built around a proprietary systemically administered immunotherapy platform, centered on its Decoy product candidates, with Decoy20 currently the lead program. The scientific concept is to deliver an intravenous therapy designed to activate anti-tumor and anti-viral immune responses. In its materials, the company highlights preclinical work showing tumor eradication when Decoy candidates were combined with PD-1 checkpoint inhibitors, low-dose chemotherapy, non-steroidal anti-inflammatory drugs, or approved targeted antibodies. Indaptus also emphasizes a safety-oriented design, noting that nonclinical toxicology studies did not show sustained induction of key cytokine release syndrome biomarkers, which may help differentiate the platform in a crowded immuno-oncology landscape. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/06/02/3091794/0/en/indaptus-therapeutics-doses-first-patient-in-phase-1b-2-combination-study-of-decoy20-with-pd-1-checkpoint-inhibitor-tislelizumab.html))
Read moreShow less
From a competitive standpoint, Indaptus operates in one of the most contested areas of biotech: immuno-oncology and antiviral immunotherapy. The company does not compete on scale, manufacturing breadth, or commercial infrastructure; instead, its value proposition rests on scientific differentiation, patent protection, and the potential to create combination regimens that improve efficacy without unacceptable toxicity. A notable strategic step was the company’s securing of new patents in China, Japan, and Israel covering Decoy bacterial compositions for the prevention or treatment of hepatitis B virus and HIV. For investors, that supports an IP-led thesis: if the platform translates into clinical benefit, the company could attract partnership interest or broader development opportunities. ([globenewswire.com](https://www.globenewswire.com/news-release/2025/03/13/3042088/0/en/indaptus-therapeutics-reports-fourth-quarter-and-year-end-2024-financial-results-and-provides-corporate-update.html))
Geographically, Indaptus is primarily based in the United States, with principal executive offices at 3 Columbus Circle in New York City; its SEC filings also reference prior office space in San Diego, California. Recent milestones underline the company’s clinical momentum. In March 2025, Indaptus said it had entered a clinical supply agreement with BeiGene to evaluate Decoy20 in combination with tislelizumab, and in June 2025 it announced dosing of the first patient in the Phase 1b/2 expansion study. Most recently, the company’s first-quarter 2026 update stressed both the promise and the risk profile of the business: development is advancing, but financing needs, going-concern risk, and the uncertain path from preclinical and early clinical data to approved products remain central investment considerations. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001857044/000149315226010585/form10-k.htm))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
